<?xml version="1.0" encoding="UTF-8"?>
<p>Safety assessments were undertaken throughout the study to address AEs, vital signs, body weight, 12‐lead electrocardiogram data, concomitant medication use, clinical laboratory values (hematology, blood biochemistry, and urinalysis), and ophthalmological findings. Adverse event severity was classified using the Common Terminology Criteria for Adverse Events, version 4.0. Ophthalmological examinations were carried out at screening, on day 15 of an odd‐numbered cycle, and if clinically indicated.</p>
